[A24-95] Epcoritamab (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V
Last updated 16.12.2024
Project no.:
A24-95
Commission:
Commission awarded on 16.09.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A24-95
| Project no. | Title | Status |
|---|---|---|
| G23-27 | Epcoritamab (relapsed or refractory diffuse large B-cell lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |